The DNA damage response (DDR) defense mechanism is a crucial way to maintain the stability of the genome. DDR defects can lead to the occurrence of various diseases, including tumors. The DDR pathway has become an anti-tumor drug target, of which the most prominent Drugs are PARP inhibitors.
The global DNA damage response drugs market has the potential to grow at propelling CAGR in the forecast period from 2020-2027. DNA damage may come from multiple sources, such as the ultraviolet rays, cigarette smoke, and other chemicals, or genotoxic drugs used in chemotherapy.
Due to various internal and environmental factors, every cell in our body produces thousands of DNA lesions every day. If lesions not repaired correctly, they may lead to mutations and wider genomic aberrations, threatening cell activity and, ultimately, cancer. In response to this threat, life has evolved a system collectively known as DNA damage response to detect DNA damage, prompt its presence, and mediate its repair.
DNA repair is essential in many biological processes, including the development of the immune system, meiotic reorganization, and the prevention of many human diseases. Inherited DNA repair defects can be catastrophic and can lead to abnormal growth, increased cancer tendencies, immune weaknesses, neurodegenerative diseases, and premature aging.
There are different types of DNA damage, so there are also DNA repairs of different molecular pathways to correct these damages, including non-homologous end, joining, homologous recombination, mismatch repair, and nucleotide excision repair. DNA repair is essential for an organism to maintain its genome integrity and function. Therefore, antibodies are the new tools to study that helps in understanding the mechanism of the cell but will also provide exciting opportunities for a better understanding of human health and disease.
Damage to DNA by ionizing radiation has direct and indirect effects. The immediate impact is that DNA directly absorbs radiation energy and is damaged. The indirect implications refer to other molecules around the DNA (mainly water molecules) that absorb radiation energy to generate free radicals with high reactivity and damage DNA. Therefore, ionizing radiation can cause various changes in DNA molecules. Thus, the market share of the DNA damage response drug market is rising due to the rising cases of skin cancer.
Antibodies are a standard tool for studying the DNA damage response. They can measure the expression and activation of essential proteins and their post-translational modifications during damage, such as H2A.X phosphorylation, which is a marker of DNA damage response. Moreover, antibodies are also widely used to determine the mechanism by which their cells localize and aggregate to damaged DNA.
Based on the type, the global DNA damage response drugs market bifurcated into PARP inhibitors, Others. The PARP inhibitors segment accounted for the largest share of the market is expected to grow at a bolstering rate during the forecast period from 2020-2027. PARP inhibitors can inhibit the repair of DNA damage of tumor cells through a synergistic lethal effect, thereby killing tumor cells, which is a safe and effective new treatment method. At present, many PARP inhibitors with good selectivity and sensitivity have developed, and most of them have entered the stage of clinical trials. Their function and efficacy are among the best in many targeted drugs, and they have become the nemesis of BRCA gene mutation tumors. However, PARP inhibitors require precise targets, and BRCA mutations only exist in breast and ovarian cancer, which has led to severe limitations in the use of PARP inhibitors as single agents.
Based on the Application, the global DNA damage response drugs market attributed to Oncological Stroke. The Oncological segment has the largest market share in the global DNA damage response drugs market. The DNA in human cells is damaged thousands of times every day due to natural or external factors to monitor and repair DNA damaged cells that have evolved DNA damage responses. Many cancers have defects in DNA damage response, which makes cells more sensitive to DNA damage and more dependent on other pathways. Traditional cancer treatments, such as radiotherapy and DNA damage chemotherapy, are based on this premise.
However, these treatments cannot identify the healthy cells and tumor cells of the human body and usually produce serious side effects and injuries. Therefore, it is necessary to develop cancer-specific DDR-dependent treatments, which can not only preferentially kill cancer cells but also reduces the impact on healthy cells. Thus, the oncological segment is fueling the market share for the global DNA damage response drugs market.
Based on geography, the global DNA damage response drugs market segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America holds the largest share of the global DNA damage response drugs market. It is mainly owing to the development and mechanism of the drug for the treatment of cancer. Also, they tested the drug on mice, and cells of mice successfully retrieve the functions of the cell. Therefore, their successful research for repairing cell’s capability has fueled the market demand for the DNA damage response drug market. Thus, North America is dominating the largest market share of the DNA damage response drug market.
Companies such as 4SC AG, Bristol Myers, ARCAGY/ GINECO GROUP, Squibb, British Columbia Cancer Agency, Genentech, Cambridge University Hospitals NHS Foundation Trust, Georgetown University, German Breast Group, GlaxoSmithKline, Jiangsu Hengrui Medicine, Johnson & Johnson, Jonsson Comprehensive Cancer Center, Karyopharm Therapeutics, KuDOS Pharmaceuticals, National Health Service, National Institutes of Health, Tesaro and others are key players in the global DNA damage response drugs market.